Generic Name and Formulations:
Alprostadil 125mcg, 250mcg, 500mcg, 1000mcg; urethral suppository.
Indications for MUSE:
Supervise titration. Initially 125–250mcg inserted in urethra after urination; adjust dose in stepwise manner on separate occasions; max 2 supps/day.
Urethral stricture. Balanitis. Severe hypospadias and curvature. Acute or chronic urethritis. Predisposition to venous thrombosis (eg, sickle cell anemia or trait). Hyperviscosity syndrome. Patients for whom sexual activity is inadvisable or contraindicated. If partner is pregnant, use condom; if partner is of childbearing age, use contraception.
Exclude reversible causes. Hypotension. Bleeding disorders. Priapism. Pregnancy (Cat.C): see Contraindications.
Effect attenuated by drugs that interfere with erectile function (eg, decongestants). Caution with anticoagulants.
Penile, urethral, or testicular pain, urethral burning, minor urethral bleeding/spotting, dizziness, hypotension, flu symptoms, rhinitis, others. Infrequent: priapism. Partners: vaginal burning/itching.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Nicotinamide and Cancer
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Opioid Prescription Protocol Decreases Opioid Use After Gynecologic Surgery
- Everolimus Plus Letrozole May Be Active in Recurrent Endometrial Carcinoma
- Affordable Care Act Increased Percentage of Insured Patients With Gynecologic Cancers
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML